LinkedInXFacebook
Subscribe
Orthopedics This Week
  • Opinions
  • |My Feed
  • |Events
  • |Company Directory
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Knee Injection Business Jumps as TKA Slumps
Company News

Knee Injection Business Jumps as TKA Slumps

By Robin YoungNovember 17, 2026 4 min read Premium comments

Advertisement

Knee Injection Business Jumps as TKA Slumps

Every supplier of knee arthroplasty products (you know who they are) are reporting an industry-wide slump in knee surgery demand. Why? OA has slumped? No, people continue to grow old, have knee injuries and gain weight. Has the ability to afford a $20-40k knee surgery and take the time off of work changed? Absolutely.

And the low cost alternative is….HA (and steroid) knee injections.

Case in point: this Bedford, Massachusetts, hyaluronic acid specialist which just announced strong HA sales, improved manufacturing performance and sharply reduced operating losses.

The main fly in the ointment was the FDA’s ruling on Hyalofast, but more about that later.

Q3 revenue reached $30.6 million, up 10% from a year earlier, while adjusted EBITDA soared to $5.1 million from $865,000.

Anika Third Quarter Financial Snapshot

MetricQ3 2026Q3 2025
Sales$30.59$27.82
Gross profit$18.84$15.58
Operating profit (loss)($0.71)($3.23)
Adjusted EBITDA$5.10$0.87
Free cash flow, calculated$6.72$4.98
Cash and cash equivalents$44.96$57.99

Dollars in millions. Earnings figures reflect continuing operations. Free cash flow equals consolidated operating cash flow less capital expenditures, calculated for each quarter from the change in year-to-date totals. Cash balances are at September 30. Adjusted EBITDA is a non-GAAP measure. Parentheses indicate losses.

More Sales With More Left Over

With higher sales, profits grew even faster. Gross profit popped 21% to $18.8 million, outpacing revenue growth. Gross margin increased to approximately 62% of sales from 56%.

Operating expenses nudged slightly higher, up 4% to $19.5 million. R&D rose, while selling, general and administrative expenses edged lower.

Operating losses improved by 78% to just $712,000 from $3.2 million.

Advertisement

GAAP (Generally Accepted Accounting Principle) operating losses just missed the profit mark coming in at $311,000, or $0.02 per share, versus $3.2 million, or $0.22 per share last year.

Adjusted EBITDA was 16.7% of revenue, versus 3.1% a year earlier.

The word “adjusted” means no consideration for stock compensation and severance expenses, among other items. Third-quarter stock compensation alone was $4.2 million.

Integrity Keeps Expanding Its Territory

Commercial Channel revenue increased 17% to $14.0 million. International osteoarthritis pain management revenue grew 19%, supported by demand for Cingal and Monovisc. Original Equipment Manufacturer, or OEM, revenue increased 5% to $16.6 million, supported by Hyvisc HA and J&J DePuy Synthes HA sales.

Integrity supplied an encouraging product story. Revenue increased more than 30% during the quarter and 37% through September. Sales over the trailing 12 months reached $7.5 million, a useful reminder that this remains a growing franchise rather than Anika’s largest business.

Larger implant sizes introduced in late 2025 and early 2026 helped expand use into other tendon applications, including foot and ankle and knee procedures. In September, Anika launched second-generation instrumentation offering another insertion and deployment option to accommodate surgeon preferences.

A Longer Contract and a Busier Factory

Anika added commercial visibility after quarter-end through a new 10-year Hyvisc distribution agreement with existing partner Boehringer Ingelheim. Announced in November, the arrangement includes higher transfer pricing, royalties on end-market sales and higher contractual purchases.

The company expects $8 million in payments: $4 million upfront in the first quarter of 2027 and another $4 million tied to commercial volumes. Those dollars belong to the future cash story, not September’s balance sheet.

Manufacturing is also getting more productive. Cross-link line unit volumes now exceed 2022 levels by more than 50%. Anika cited FDA approval of new aseptic manufacturing processes and validation of a second cross-link filler. It also resumed U.S. shipments of Hyalomatrix, a Hyaff wound product, through a new OEM distributor.

Cash Improves During the Quarter

Advertisement

Calculated third-quarter free cash flow reached $6.7 million, up from $5.0 million. Operating cash flow of $8.4 million covered $1.7 million of capital expenditures.

Cash ended September at $45.0 million, below the $58.0 million held a year earlier. Over the first nine months, Anika spent $9.5 million repurchasing shares and built inventory to support demand. Inventory reached $30.4 million, compared with $18.8 million at December 31, 2025.

The quarterly cash recovery is welcome, although nine-month free cash flow remained negative at approximately $1.7 million. Building safety stock supports future sales, but the cash leaves before the product does.

Hyalofast Faces a Harder Path

The most consequential pipeline development arrived in October, when the FDA notified Anika that its Hyalofast premarket approval application was not approvable, primarily because of the clinical data submitted.

Anika is assessing regulatory options and discussing what additional evidence the agency may require. The announcement offers no new U.S. approval timetable. Commercial enthusiasm cannot resolve that evidence question.

Cingal advanced on a separate track. Enrollment in its bioequivalence study finished in September. Anika expects to submit a new drug application before year-end 2027, following the clinical study report and required chemistry, manufacturing and controls work. That is a filing target, not an approval date.

A Stronger Outlook With a Quieter 2027

Anika raised the lower end of its 2026 revenue growth forecast to 6%, leaving the upper end at 10%. Expected adjusted EBITDA margin increased to 15%–17%, from 13%–17%.

The mix shifted, however. OEM growth guidance increased to 5%–9% from 0%–5%, while Commercial Channel guidance dropped to 9%–13% from 12%–18%. For 2027, total revenue growth remains projected at flat to 5%.

Anika is selling more and retaining more gross profit from each sales dollar. Integrity gives surgeons an expanding toolkit, and the Hyvisc agreement improves commercial visibility. Sustaining that progress will require stronger cash generation and continued execution, while Hyalofast’s U.S. prospects depend on answering the FDA’s clinical concerns.

Source: Anika Therapeutics, Inc.

Author

RY
Robin Young

Why This Matters

Two Perspectives

MBA Lens: Economic and industry impact

The orthopedic market is seeing a shift from total knee arthroplasty (TKA) to lower-cost knee injections, driven by patient affordability and time-off constraints. Anika is strategically capitalizing on this trend, reporting strong Q3 revenue growth of 10% to $30.6 million and a significant EBITDA increase to $5.1 million. Their improved gross margins and new 10-year Hyvisc distribution agreement enhance commercial visibility and profitability.

  • Anika's strategy leverages the market's pivot to non-surgical OA treatments, boosting HA product sales and financial performance.
  • The company secured a long-term distribution deal for Hyvisc, ensuring future revenue and market presence in the knee injection segment.

PhD Lens: Clinical and outcomes impact

The article highlights the increasing adoption of hyaluronic acid (HA) and steroid knee injections as a non-surgical alternative to TKA for osteoarthritis. Anika's Hyalofast premarket approval application was deemed "not approvable" by the FDA, primarily due to insufficient clinical data. This underscores the critical need for robust clinical evidence for new orthopedic biomaterials and treatment modalities to gain regulatory clearance.

  • FDA rejected Hyalofast's application due to clinical data deficiencies, emphasizing rigorous evidence requirements for market entry.
  • Cingal's bioequivalence study enrollment is complete, with an NDA submission targeted by end of 2027, indicating ongoing clinical development.
React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

Orthopedics This Week’s mission is to connect the orthopedic community with the people, ideas, and innovations shaping the future of musculoskeletal care.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Opinions
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, opinions, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy